Deep Intramuscular Rocuronium Administration
Rocuronium is FDA-approved for intravenous use only and is NOT recommended for routine intramuscular administration. 1
FDA-Approved Route
The FDA label explicitly states rocuronium is "for intravenous use only" 1. The prescribing information contains no approved intramuscular dosing regimen, and all standard dosing recommendations are for IV administration 1.
Clinical Context for IM Use
Despite the lack of FDA approval, intramuscular rocuronium has been studied in emergency situations where IV access is unavailable, particularly for:
- Laryngospasm without IV access
- Emergency airway management when succinylcholine is unavailable
Evidence for IM Administration
Pediatric data shows inconsistent results:
The most rigorous multicenter study 2 demonstrated that IM rocuronium does not consistently provide satisfactory intubating conditions in infants and children. Using doses of 1.0 mg/kg (infants) and 1.8 mg/kg (children) injected into the deltoid:
- Only 9 of 16 infants had adequate conditions at 3.5 minutes
- Only 10 of 17 children had adequate conditions at 4 minutes
- The study concluded IM rocuronium "is not an adequate alternative to intramuscular succinylcholine when rapid intubation is necessary" 2
Pharmacokinetic limitations:
- Bioavailability is only 82.6% via IM route 3
- Peak plasma concentration occurs at 13 minutes 3
- Complete twitch depression takes 7-8 minutes 2
- Duration is prolonged: 79 minutes in infants, 86 minutes in children 2
Site of injection matters critically:
- Deltoid injections show faster onset than quadriceps 4
- Quadriceps injections resulted in slow, unreliable onset 4
Management Recommendations
When IV Access is Unavailable
First-line approach:
- Prioritize obtaining IV access immediately
- Consider intraosseous access as alternative to IM route
- Use succinylcholine IM if available (1.5-2 mg/kg deltoid is the established emergency alternative)
If IM rocuronium must be used (last resort only):
- Dose: 1.0 mg/kg (infants) or 1.8 mg/kg (children) into deltoid muscle 4, 2
- Timing: Allow 3.5-4 minutes before attempting intubation 2
- Expect: Prolonged paralysis (79-86 minutes to 25% recovery) 2
- Monitor: Be prepared for inadequate intubating conditions in up to 50% of patients 2
Critical Caveats
- Avoid quadriceps injection - unreliable onset 4
- Not suitable for rapid sequence intubation - onset too slow and unpredictable 2
- Prolonged paralysis risk - these large doses produce extended neuromuscular blockade 4, 2
- Have sugammadex available - though reversal during "cannot intubate, cannot oxygenate" is not reliable 5
Case Report Context
One 2024 case report 6 described successful use of 1.0 mg/kg IM rocuronium for laryngospasm in an 11-month-old, with mask ventilation possible within 1 minute. However, this single case does not override the multicenter trial data showing inconsistent results 2.
Bottom Line
IM rocuronium should be considered only as an absolute last resort when IV/IO access is impossible, succinylcholine is unavailable, and the airway emergency cannot be managed by other means. The evidence shows it is unreliable, slow, and produces prolonged paralysis. Current airway guidelines 7, 5 emphasize neuromuscular blockade for airway management but do not endorse IM rocuronium as a standard approach.